Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | FABP1 | P07148 | 1/20 | 0.49 |
| ▸ | FABP6 | P51161 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764317 | 0.88 | ALDH1A1 (0.62) | CXCR4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL11563461 | 0.85 | NOS2 (0.58) | CXCR4KDM4EALDH1A1HPGDFABP1 | |
| SCHEMBL18772850 | 0.83 | ALDH1A1 (0.57) | CXCR4KDM4EALDH1A1HPGDFABP1 | |
| SCHEMBL11563242 | 0.82 | KMT2A (0.60) | CXCR4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL22602024 | 0.82 | ALDH1A1 (0.51) | CXCR4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL12832039 | 0.82 | ALDH1A1 (0.51) | CXCR4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL11561740 | 0.82 | POLB (0.60) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL10055043 | 0.81 | KDM4E (0.64) | CXCR4KDM4EALDH1A1FABP1FABP6 | |
| SCHEMBL16001177 | 0.81 | ALDH1A1 (0.57) | CXCR4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL10055029 | 0.81 | GPR55 (0.59) | CXCR4KDM4EALDH1A1HPGDFABP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013070660-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| US-8080659-B2 | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | EMORY UNIVERSITY | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | CXCR4, CXCL12, CCR5 | CXCR4 1/4885KDM4E 3897/4885ALDH1A1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.